DARE - Dare Bioscience Inc Stock Price, Fair Value and News

0.49USD+0.05 (+11.36%)Delayed

Market Summary

USD0.49+0.05

Delayed

11.36%

DARE Stock Price

View Fullscreen

DARE RSI Chart

DARE Valuation

Market Cap

49.5M

Price/Earnings (Trailing)

-1.71

Price/Sales (Trailing)

17.64

Price/Free Cashflow

-1.64

DARE Price/Sales (Trailing)

DARE Profitability

Return on Equity

262.91%

Return on Assets

-222.24%

Free Cashflow Yield

-60.92%

DARE Fundamentals

DARE Revenue

Revenue (TTM)

2.8M

Rev. Growth (Qtr)

80.79%

DARE Earnings

Earnings (TTM)

-28.9M

Earnings Growth (Yr)

15.45%

Earnings Growth (Qtr)

-34.45%

Breaking Down DARE Revenue

Last 7 days

58.1%

Last 30 days

75%

Last 90 days

36.1%

Trailing 12 Months

-52.0%

How does DARE drawdown profile look like?

DARE Financial Health

Current Ratio

0.56

DARE Investor Care

Shares Dilution (1Y)

17.16%

Diluted EPS (TTM)

-0.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	7.6M	0	5.2M	2.8M
2022	4.1M	6.0M	8.0M	10.0M
2021	95.8K	100.0K	100.0K	2.1M
2020	420.8K	308.3K	195.8K	83.3K
2019	637.5K	550.0K	683.3K	533.3K
2018	3.0M	2.5M	992.0K	625.0K
2017	2.5M	2.9M	0	0
2016	0	283.0K	250.0K	1.0M
2014	407.0K	298.0K	189.0K	80.0K
2013	0	0	0	516.0K
2012	0	0	0	625.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Dare Bioscience Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2019	hawley roger	bought	500,000	1.1	454,545	-

Which funds bought or sold DARE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	5,763	5,763	-%
May 15, 2024	STATE STREET CORP	unchanged	-	44,885	121,427	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-45.00	-	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	23,000	62,000	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-46.72	-13.00	72.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-20.45	2,062	9,949	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	16,320	16,320	-%
May 15, 2024	Zuckerman Investment Group, LLC	sold off	-100	-7,126	-	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	79,058	79,058	-%

Are Funds Buying or Selling DARE?

Are funds buying DARE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DARE

No. of Funds

Unveiling Dare Bioscience Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2022	vanguard index funds	3.99%	3,056,053	SC 13G/A
Feb 09, 2022	vanguard group inc	3.99%	3,056,053	SC 13G/A
Feb 12, 2021	polaris venture partners iii lp	2.4%	1,142,961	SC 13G/A
Feb 10, 2021	vanguard group inc	7.88%	2,993,275	SC 13G
Feb 09, 2021	hudson bay capital management lp	0.92%	382,500	SC 13G/A
Feb 08, 2021	vanguard index funds	7.11%	2,700,357	SC 13G
Apr 01, 2020	hawley roger	4.4%	1,095,105	SC 13D/A
Feb 21, 2020	dare bioscience, inc.	4.5%	1,094,937	SC 13D/A
Feb 12, 2020	polaris venture partners iii lp	4.7%	1,142,961	SC 13G
Dec 09, 2019	dare bioscience, inc.	5.5%	1,084,956	SC 13D/A

Recent SEC filings of Dare Bioscience Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 10, 2024	EFFECT	EFFECT
May 10, 2024	424B5	Prospectus Filed
May 01, 2024	EFFECT	EFFECT
May 01, 2024	424B3	Prospectus Filed
Apr 30, 2024	8-K	Current Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Dare Bioscience Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Dare Bioscience Inc News

Latest updates

Dare Bioscience Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-100.0%	-	1,807,885	1,000,000	500,000	-	-	10,000,000	6,675,000	3,350,000	25,000	25,000	25,000	25,000	25,000	20,833	72,917	125,001	133,333	162,500	112,500	275,000
Operating Expenses	-13.6%	6,031,775	6,979,345	9,396,415	8,382,649	16,230,568	7,138,793	9,615,678	8,400,449	9,543,115	12,668,937	9,162,926	7,693,534	8,440,535	7,581,822	7,125,831	4,254,069	3,860,810	3,418,549	3,982,451	3,083,071	2,958,558
S&GA Expenses	-100.0%	-	3,154,814	2,696,779	3,337,426	3,228,847	2,651,543	2,792,894	2,569,987	2,401,646	2,211,334	1,797,637	1,940,328	1,777,126	1,353,069	1,557,548	1,861,765	1,361,893	1,318,986	1,307,379	1,277,180	1,020,425
R&D Expenses	-12.4%	3,328,520	3,799,531	6,674,636	5,020,223	12,976,721	4,462,250	6,797,784	5,805,462	7,116,469	10,432,603	7,340,289	5,728,206	6,638,409	6,203,753	5,547,450	2,379,804	2,373,916	1,966,230	2,512,572	1,693,391	1,663,133
EBITDA Margin	-	-	-	-	-	-	-	-386	-386	-386	-	-	-280	-322	-70.10	-44.52	-32.62	-25.74	-23.82	-29.60	-25.53	-26.04
EBT Margin	-	-	-	-	-	-	-	-386	-386	-386	-	-	-285	-328	-72.84	-46.26	-33.89	-26.74	-24.61	-30.57	-26.37	-26.90
Net Income	-34.5%	-6,800,000	-5,057,562	-8,299,096	-8,042,501	-15,943,223	-7,019,843	413,998	-8,398,670	-9,542,281	-12,667,429	-9,162,751	-7,323,644	-8,441,474	-7,582,808	-7,124,213	-4,252,248	-3,866,462	-3,393,078	-3,952,450	-3,051,840	-2,916,552
Net Income Margin	4.1%	-10.30	-10.74	-7.89	-4.02	-3.09	-3.06	-5.00	-9.80	-18.60	-375	-325	-317	-328	-	-	-	-	-	-	-	-
Free Cashflow	22.5%	-6,807,296	-8,786,236	-7,995,930	-16,117,571	-5,899,369	8,545,226	-8,449,329	-12,348,026	-9,915,899	1,305,807	-11,791,454	-8,377,015	-9,196,127	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-38.9%	13.00	21.00	25.00	23.00	30.00	44.00	50.00	51.00	49.00	56.00	49.00	15.00	11.00	8.00	8.00	9.00	10.00	7.00	4.00	7.00	5.00
Current Assets	-43.1%	10.00	18.00	22.00	22.00	30.00	43.00	50.00	50.00	48.00	55.00	48.00	14.00	10.00	7.00	7.00	8.00	9.00	6.00	3.00	7.00	4.00
Cash Equivalents	-62.1%	4.00	10.00	14.00	13.00	20.00	35.00	40.00	32.00	39.00	52.00	46.00	9.00	8.00	5.00	5.00	5.00	5.00	5.00	2.00	6.00	4.00
Net PPE	-92.0%	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-8.8%	24.00	26.00	27.00	26.00	25.00	33.00	24.00	18.00	18.00	17.00	17.00	7.00	7.00	9.00	9.00	8.00	7.00	7.00	2.00	2.00	1.00
Current Liabilities	-13.5%	18.00	20.00	26.00	25.00	24.00	32.00	23.00	17.00	16.00	16.00	16.00	6.00	6.00	8.00	8.00	6.00	5.00	6.00	2.00	2.00	1.00
Shareholder's Equity	-117.9%	-11.00	-5.05	-	-	5.00	11.00	26.00	33.00	31.00	39.00	32.00	8.00	3.00	-	-	0.00	3.00	0.00	2.00	5.00	4.00
Retained Earnings	-3.9%	-177	-171	-166	-157	-149	-141	-125	-118	-118	-110	-100	-87.90	-78.75	-71.43	-62.99	-55.40	-48.28	-44.02	-40.20	-36.76	-32.02
Additional Paid-In Capital	0.5%	167	167	164	156	154	153	152	151	150	149	133	96.00	82.00	70.00	62.00	56.00	52.00	45.00	42.00	42.00	36.00
Shares Outstanding	0.6%	101	100	98.00	87.00	86.00	85.00	86.00	85.00	84.00	84.00	71.00	50.00	45.00	42.00	-	-	-	-	-	-	-
Float	-	-	-	-	77.00	-	-	-	102	-	-	-	86.00	-	-	-	23.00	-	-	-	12.00	-

Cashflow (Last 12 Months)

(In )

Cashflow (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	16.9%	-6,800,000	-8,178,905	-7,973,831	-6,586,347	-16,117,571	-5,896,672	8,600,229	-8,448,513	-12,343,473	-9,915,899	1,320,331	-11,791,454	-8,377,015	-9,193,748	-5,356,712	-4,086,918	-6,597,546	-3,808,683	-3,180,071	-3,018,242	-3,308,484
Share Based Compensation	1.3%	627,700	619,791	636,086	650,186	624,621	532,133	556,448	537,521	532,409	388,806	439,497	405,478	365,911	199,449	194,882	186,859	160,841	117,527	135,393	111,351	97,968
Cashflow From Investing	98.8%	-7,296	-607,331	-22,099	-	-	-2,697	-55,003	-816	-4,553	-	-14,524	-	-	-2,379	-	-	-	6,143,893	-	-	-
Cashflow From Financing	-99.7%	14,032	5,309,268	8,576,282	452,195	1,299,375	-1.00	4,456	1,338,899	-	16,003,788	35,216,514	13,251,924	11,374,540	8,454,761	5,398,582	4,389,621	6,887,708	-	-	5,151,702	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DARE Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Royalty revenue	License [Member]
Revenue
Total revenue	$ 9,302	$ 0
Total revenue	9,302	0
Operating expenses
General and administrative	2,670,581	3,337,426
Research and development	3,328,520	5,020,223
Royalty expense	7,674	0
License fee expense	25,000	25,000
Total operating expenses	6,031,775	8,382,649
Loss from operations	(6,022,473)	(8,382,649)
Other income (expense)	(732,883)	340,148
Net loss	(6,755,356)	(8,042,501)
Foreign currency translation adjustments	(39,227)	(22,005)
Comprehensive loss	$ (6,794,583)	$ (8,064,506)
Loss per common share - basic (in usd per share)	$ (0.07)	$ (0.09)
Loss per common share - diluted (in usd per share)	$ (0.07)	$ (0.09)
Weighted average number of shares outstanding:
Basic (in shares)	100,514,272	85,517,540
Diluted (in shares)	100,514,272	85,517,540

DARE Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 3,630,603	$ 10,476,056
Other receivables	1,385,672	949,211
Prepaid expenses	4,814,082	6,118,272
Other current assets	152,204	0
Total current assets	9,982,561	17,543,539
Property and equipment, net	52,493	655,975
Deposits	762,432	1,163,477
Operating lease right-of-use assets	1,560,706	1,319,630
Other non-current assets	654,530	599,594
Total assets	13,012,722	21,282,215
Current liabilities
Accounts payable	4,040,509	3,385,551
Accrued expenses	1,370,465	2,889,005
Royalties payable	7,674	0
Deferred grant funding	11,835,871	13,737,154
Current portion of lease liabilities	470,390	468,726
Total current liabilities	17,724,909	20,480,436
Deferred revenue, non-current	1,000,000	1,000,000
Liability related to the sale of future royalties, net	4,115,631	3,913,676
Lease liabilities long-term	1,171,592	935,743
Total liabilities	24,012,132	26,329,855
Commitments and contingencies (Note 8)
Stockholders' equity (deficit)
Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding	0	0
Common stock, $0.0001 par value; 240,000,000 shares authorized; 100,581,900 and 99,973,932 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	10,058	9,997
Accumulated other comprehensive loss	(400,123)	(360,896)
Additional paid-in capital	167,382,042	166,539,290
Accumulated deficit	(177,991,387)	(171,236,031)
Total stockholders' equity (deficit)	(10,999,410)	(5,047,640)
Total liabilities and stockholders' equity (deficit)	$ 13,012,722	$ 21,282,215

About Dare Bioscience Inc

DarÃƒÂ© Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy. The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. DarÃƒÂ© Bioscience, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

CEO	Ms. Sabrina Martucci Johnson
WEBSITE	darebioscience.com
INDUSTRY	Biotechnology
EMPLOYEES	25

Dare Bioscience Inc Frequently Asked Questions

What is the ticker symbol for Dare Bioscience Inc? What does DARE stand for in stocks?

DARE is the stock ticker symbol of Dare Bioscience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dare Bioscience Inc (DARE)?

As of Fri May 17 2024, market cap of Dare Bioscience Inc is 49.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DARE stock?

You can check DARE's fair value in chart for subscribers.

What is the fair value of DARE stock?

You can check DARE's fair value in chart for subscribers. The fair value of Dare Bioscience Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Dare Bioscience Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DARE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Dare Bioscience Inc a good stock to buy?

The fair value guage provides a quick view whether DARE is over valued or under valued. Whether Dare Bioscience Inc is cheap or expensive depends on the assumptions which impact Dare Bioscience Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DARE.

What is Dare Bioscience Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, DARE's PE ratio (Price to Earnings) is -1.71 and Price to Sales (PS) ratio is 17.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DARE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Dare Bioscience Inc's stock?

In the past 10 years, Dare Bioscience Inc has provided -0.384 (multiply by 100 for percentage) rate of return.